Despite abundant trials, thrombopoietin has not been begin to be advantageous therapeutically. Theoretical uses cover the accretion of platelets for donation, accretion of platelet counts afterwards myelosuppressive chemotherapy.
Trials of a adapted recombinant form, megakaryocyte advance and adverse agency (MGDF), were chock-full if advantageous volunteers developed autoantibodies to autogenous thrombopoietin and again developed thrombocytopenia. Romiplostim and Eltrombopag, structurally altered compounds that activate the aforementioned pathway, are acclimated instead.
A quadrivalent peptide alternation is getting investigated, as able-bodied as several small-molecule agents, and several non-peptide ligands of c-Mpl, which act as thrombopoietin analogues.